CRISPR Therapy Durably Lowers ANGPTL3 in Primates
A single-dose base-editing treatment cut circulating ANGPTL3 protein by more than 90% in nonhuman primates, with effects lasting three years.
Updated on Nov. 6, 2026 in Biotech
Live Poll
Would you accept a one-time gene-editing treatment for high cholesterol if it were proven safe?
Researchers reported a single-dose CRISPR base-editing therapy that inactivated the ANGPTL3 gene in nonhuman primates, reducing circulating ANGPTL3 protein by more than 90% on average. A first-in-human clinical trial in patients with refractory hyperlipidemia syndromes is ongoing.
Why it matters
Circulating LDL-C and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease, and most patients fail to reach target lipid levels with approved lipid-lowering medications. A durable, single-dose option could address that gap if the approach proves safe and effective in people.
The therapy is delivered as a GalNAc-lipid nanoparticle infusion of guide RNA and mRNA encoding a CRISPR adenine base editor that introduces a single DNA base-pair change at the ANGPTL3 locus. In human liver cells in vitro, no detectable off-target editing was found at approximately 3000 candidate sites and no treatment-related structural variants were detected, though human in vivo safety data remain unavailable.
The players
CRISPR base editing
A gene-editing approach that chemically changes individual DNA base pairs without cutting both strands of the DNA, offering a potentially more precise alternative to earlier CRISPR methods.
The details
The base editor is liver-selective in its inactivation of ANGPTL3, and targeted inactivation was well-tolerated in nonhuman primates. The reduction in circulating ANGPTL3 protein was confirmed durable out to three years after a single dose.
Timeline
Durability of ANGPTL3 reduction was confirmed in nonhuman primates out to 3 years after a single dose.
Tech Race
This therapy extends CRISPR adenine base editors, a precision successor to earlier double-strand-break CRISPR methods, into a liver-targeted treatment for lipid disorders. It positions gene editing as a possible one-time alternative to chronic lipid-lowering drugs, a shift the field has been pursuing since base editors first reached animal studies.
For patients with high LDL-C or triglycerides that current medications cannot control, a one-time therapy could in principle replace years of daily pills and frequent monitoring. Access and cost are not addressed in the source, and the approach remains investigational until human trial results are available.
The takeaway
Gene editing targeting ANGPTL3 has shown durable lipid lowering in animals, but readers should treat it as early-stage until human trial data arrive. The first-in-human results will determine whether the preclinical promise holds.
Further reading
For more on the research behind this approach, explore our Biotech coverage.
Source note: This article includes information reported by Nature.
Live Poll
Would you accept a one-time gene-editing treatment for high cholesterol if it were proven safe?
